Targeting specific genetic weaknesses in kidney cancer
Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma
This study is looking at how specific genetic changes in clear cell kidney cancer can be targeted to create better treatments, especially focusing on a gene called SETD2 that is important for patient outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11005208 on NIH RePORTER |
What this research studies
This research investigates how certain genetic mutations in clear cell renal cell carcinoma (ccRCC) can be targeted for treatment. It focuses on the loss of the SETD2 gene, which is linked to poor outcomes in patients. By using advanced techniques like CRISPR/Cas9, the study aims to identify vulnerabilities in cancer cells that can be exploited for therapeutic purposes. The goal is to develop new treatment strategies that specifically address these genetic weaknesses, potentially improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma who have specific genetic mutations, particularly in the SETD2 gene.
Not a fit: Patients with renal cell carcinoma that does not have actionable mutations or those with other types of kidney cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with clear cell renal cell carcinoma, improving survival rates and treatment efficacy.
How similar studies have performed: Other research has shown promise in targeting genetic vulnerabilities in cancer, making this approach both innovative and grounded in previous successes.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Robertson, Keith D — Mayo Clinic Rochester
- Study coordinator: Robertson, Keith D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.